From Discovery to Phase II Validation

NX-104: Biomarker-Driven Precision

Lead candidate NX-104 exhibits high biomarker selectivity in ongoing Phase II trials, targeting specific molecular pathways for advanced solid tumors. Data supports a favorable safety profile.

NX-208: Modulating Immune Response

Our immunology candidate, NX-208, focuses on modulating specific immune checkpoints. Preclinical data indicates a novel mechanism for autoimmune disease intervention.

NX-301: Orphan Indication Focus

NX-301 addresses a critical unmet need in a rare genetic disorder. Early-stage studies demonstrate promising target engagement and disease modification potential.

Rigorous Clinical Validation Gates

Discovery & Preclinical

Phase I: Safety & Dose

Phase II: Efficacy & Biomarkers

Regulatory & Pivotal Studies

Identification of novel molecular targets and comprehensive in vitro/in vivo studies to establish proof-of-concept and safety parameters.

First-in-human trials to assess drug safety, tolerability, pharmacokinetics, and initial dose-finding in healthy volunteers.

Evaluation of therapeutic efficacy in patient populations, focusing on biomarker response and optimal dosing for pivotal studies.

Preparation for regulatory submissions and design of large-scale Phase III trials to confirm clinical benefit and long-term safety.

Access Peer-Reviewed Trial Documentation

For institutional partners, clinical investigators, and regulatory bodies, detailed protocols and comprehensive data summaries are available for review.